Orthofix Medical Inc. (NASDAQ: OFIX) is a Healthcare company (Medical - Devices) with a market capitalization of $272M. The Maz Rating grades it against the other companies in its sector.
Orthofix Medical Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.67, Orthofix Medical Inc. trades at 0.3x sales and 0.6x book value, with an EV/EBITDA of 4.4. Over the last twelve months it generated about $834M of revenue and a net loss of $45M. It runs a gross margin of 69.2%, an operating margin of -0.6% and a net margin of -5.4%. It shows return on equity of -10.3%, return on invested capital of -0.8% and a free cash flow yield of -16.1%. On the balance sheet: a debt-to-equity ratio of 0.55 and a current ratio of 3.11. Over the past 52 weeks the share price ranged from $6.52 to $16.42, with a beta of 0.64.
Orthofix Medical Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 8 Buy and 9 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Orthofix Medical Inc. (OFIX) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 62.7% / 30% · (Cash+Inv) / Mkt Cap (36m) 23.0% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 62.7% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 23.0% / 33% · Receivables / Mkt Cap (36m) 35.2% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 62.7% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 23.0% / 33.33% · Receivables / Mkt Cap (24m) 35.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 25.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 11.3% / 33.33% · Receivables / Avg Assets (4Q) 15.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 27.4% / 33.33% · (Cash+ST Inv) / Total Assets 10.1% / 33.33% · (Cash+Recv) / Total Assets 25.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Orthofix Medical Inc. (OFIX) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. Orthofix Medical Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
Orthofix Medical Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.